OPKO HEALTH, INC. (OPK) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.62

From 52W high−1.18%

Volume5.03M

Market cap$1.25B

P/E (TTM)—

P/S (TTM)2.1x

Div yield—

Key dataSep 18, 2026

Open

$1.62

From 52W high

−1.18%

Volume

5.03M

Market cap

$1.25B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

28.8x

P/E (TTM)

—

RSI (14)

62.0

MomentumView details →

1D Return

+3.09%

YTD Return

+30.02%

SummaryUpdated Jun 1, 2026

OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company founded in 1991 and headquartered in Miami, Florida. The company went public in 1995 and operates through two primary business segments: diagnostics and pharmaceuticals. OPKO has evolved from a traditional pharmaceutical company into a broader healthcare enterprise that combines laboratory testing services with drug development and commercialization. The company operates internationally across the United States, Ireland, Chile, Spain, Israel, and Mexico, serving healthcare providers, patients, and pharmaceutical partners through its integrated platform of diagnostic services and therapeutic products.

Ask drillr about OPKO HEALTH, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

28.8x

EV/Sales

2.3x

P/S (TTM)

2.1x

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

30.98%

Net Margin

−12.40%

EBITDA Margin

7.90%

ROE (TTM)

−6.16%

ROA (TTM)

−3.98%

Asset Turnover

0.32x

GrowthView details →

Revenue YoY

−11.47%

EPS YoY

+59.27%

FCF YoY

+48.31%

Revenue CAGR 3Y

−15.45%

EPS CAGR 3Y

—

EBITDA YoY

−21.93%

MomentumView details →

1D Return

+3.09%

YTD Return

+30.02%

1Y Return

+12.98%

RSI (14)

62.0

vs 50D SMA

+16.18%

vs 200D SMA

+25.46%

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

3.35x

Quick Ratio

2.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.01

EPS Surprise

87.50%

Beats (12Q)

6/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

69.79%

Rev Surprise

24.59%

Financials snapshotView financials →

Revenue (TTM)

587.89M

Net Income (TTM)

−72.89M

Op. CF (TTM)

−123.38M

Next earningsNov 4, 2026 →

Latest newsMore news →

OPKO Health secured $125 million in financing against its mazdutide royalties, obtaining non-dilutive capital while retaining longer-term royalty upside.33d ago

OPKO Health issued $125 million in notes to HealthCare Royalty, secured by royalty interests in Mazdutide, to raise non-dilutive capital.38d ago

Similar companies

Castle Biosciences, Inc.CSTL Personalis, Inc.PSNL Aclaris Therapeutics, Inc.ACRS NeoGenomics, Inc.NEO Fulgent Genetics, Inc.FLGT China Biotech Services Holdings Limited08037.HK Find similar companies →

Latest newsMore news →

OPKO Health secured $125 million in financing against its mazdutide royalties, obtaining non-dilutive capital while retaining longer-term royalty upside.33d ago OPKO Health issued $125 million in notes to HealthCare Royalty, secured by royalty interests in Mazdutide, to raise non-dilutive capital.38d ago Cocrystal Pharma announced a $5 million private placement with OPKO Health, which increased its investment in the company.48d ago